Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v9-FR | Version v4-EN | |
|---|---|---|
| Language | French | English |
| Date Updated | 2017-11-15 | 2017-09-29 |
| Drug Identification Number | 02266342 | 02266342 |
| Brand name | FLUMAZENIL INJECTION | FLUMAZENIL INJECTION |
| Common or Proper name | Flumazenil Injection, USP 0.1mg/mL MD Vial | Flumazenil Injection, USP 0.1mg/mL MD Vial |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | FLUMAZENIL | FLUMAZENIL |
| Strength(s) | 0.1MG | 0.1MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS | INTRAVENOUS |
| Packaging size | 5mL | 5mL |
| ATC code | V03AB | V03AB |
| ATC description | ALL OTHER THERAPEUTIC PRODUCTS | ALL OTHER THERAPEUTIC PRODUCTS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2017-10-10 | 2017-10-10 |
| Actual start date | 2017-10-10 | |
| Estimated end date | 2017-11-15 | 2017-11-15 |
| Actual end date | 2017-11-17 | |
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Stock available for direct orders on Friday November 17, 2017 and in all distribution centers on Tuesday November 21, 2017. | Product on reduced allocation. Sandoz Canada Inc. is the alternate supplier of Flumazenil Injection, USP 0.1mg/mL and has been notified of our shortage. Sandoz will be limiting order quantities to help ensure consistent supply to the market until our return. |
| Health Canada comments |